Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01923506 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
A Phase 1 study of Recurrent Prostate Cancer and Stage I Prostate Cancer, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT01923506: Active Phase 1 study of Recurrent Prostate Cancer and Stage I Prostate Cancer, sponsored by City of Hope Medical Center.
NCT01923506 is a Phase 1 study of Recurrent Prostate Cancer and Stage I Prostate Cancer that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 26 participants, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01923506, a Phase 1 study of Recurrent Prostate Cancer and Stage I Prostate Cancer, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with prostate cancer after undergoing surgery. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
Primary Outcome
Tables will be created to summarize these toxicities and side effects by dose level.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- RADIATION stereotactic body radiation therapy
- PROCEDURE quality-of-life assessment
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-11-25 |
| Est. Completion | 2026-07-28 |
| Phase | Phase 1 |
What the registry record for NCT01923506 still lists
NCT01923506 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (81% lower).
The record links to 5 conditions, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01923506 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01923506 about?
NCT01923506 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery". This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with prostate cancer after undergoing surgery. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
What is the current status of trial NCT01923506?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-11-25. Estimated completion is 2026-07-28.
What conditions does trial NCT01923506 study?
This clinical trial studies the following conditions: Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage III Prostate Cancer, Stage IIB Prostate Cancer, Stage IIA Prostate Cancer.
What interventions are being tested in trial NCT01923506?
The interventions under investigation include: laboratory biomarker analysis (OTHER), stereotactic body radiation therapy (RADIATION), quality-of-life assessment (PROCEDURE).
Who is sponsoring clinical trial NCT01923506?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01923506 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01923506's enrollment target sits among peer trials
26 14th of 21 higher than 8 of 21 other Recurrent Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
RECRUITING · Phase 1
-
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
RECRUITING · Phase 1
-
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI